Track topics on Twitter Track topics that are important to you
Faron Pharmaceuticals Ltd (LON:FARN) said it is planning to provide its lead drug on a compassionate use basis once its phase III clinical trial has concluded. The study, codenamed INTEREST, should be wrapped up in the fourth-quarter. It was set up to assess the efficacy of Traumakine in treating acute respiratory distress syndrome (ARDS). Faron said in its latest release that the independent data monitoring committee (IMDC) overseeing the clinical investigation has said the trial should continue unchanged. Unment medical need This is consistent with its four previous recommendations. Faron plans to treat 300 ARDS patients with Traumakine, which performed well in an earlier phase II clinical study. ARDS is severe lung condition that often results from pneumonia and has mortality rate of 30-45% with 300,000 cases annually in Europe and the US. "We are very pleased to receive the IDMC's recommendation that the INTEREST study should continue as planned,” said Faron chief executive, Dr Markku Jalkanen. “The trial is now moving into its final stages and we look forward to closing recruitment during the fourth quarter of 2017.”NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...